S
Scot A. Marsters
Researcher at Genentech
Publications - 72
Citations - 17369
Scot A. Marsters is an academic researcher from Genentech. The author has contributed to research in topics: Receptor & Apoptosis. The author has an hindex of 43, co-authored 68 publications receiving 16712 citations.
Papers
More filters
Journal ArticleDOI
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi,Roger Pai,Sharon Fong,Susan Leung,David A. Lawrence,Scot A. Marsters,Christine Blackie,Ling Chang,Amy E. McMurtrey,Andrea Hebert,Laura DeForge,Iphigenia Koumenis,Derf Lewis,Louise A. Harris,Jeanine L. Bussiere,Hartmut Koeppen,Zahra Shahrokh,Ralph H. Schwall +17 more
TL;DR: Apo2L may have potent anticancer activity without significant toxicity toward normal tissues, and cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation.
Journal ArticleDOI
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family *
Robert M. Pitti,Scot A. Marsters,Siegfried Ruppert,Christopher J. Donahue,Alison Moore,Avi Ashkenazi +5 more
TL;DR: Results suggest that, along with other family members such as Fas/Apo-1 ligand and TNF, Apo-2L may serve as an extracellular signal that triggers programmed cell death.
Journal ArticleDOI
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
James P. Sheridan,Scot A. Marsters,Robert M. Pitti,Austin L. Gurney,Maya Skubatch,Daryl T. Baldwin,Lakshmi Ramakrishnan,Christa L. Gray,Kevin P. Baker,William I. Wood,Audrey Goddard,Paul J. Godowski,Avi Ashkenazi +12 more
TL;DR: A cell surface mechanism exists for the regulation of cellular responsiveness to pro-apoptotic stimuli in tumor cells.
Journal ArticleDOI
Designing CD4 immunoadhesins for AIDS therapy
Daniel J. Capon,Steven M. Chamow,Joyce Mordenti,Scot A. Marsters,Timothy J. Gregory,Hiroaki Mitsuya,Randal A. Byrn,Catherine Lucas,Florian M. Wurm,Jerome E. Groopman,Samuel Broder,Douglas H. Smith +11 more
TL;DR: A newly-constructed antibody-like molecule containing the gp!20-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes, making it a good candidate for therapeutic use.
Journal ArticleDOI
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
Robert M. Pitti,Scot A. Marsters,David A. Lawrence,Margaret Ann Roy,Frank C. Kischkel,Patrick Dowd,Arthur J Huang,Christopher J. Donahue,Steven Sherwood,Daryl T. Baldwin,Paul J. Godowski,William I. Wood,Austin L. Gurney,Kenneth J. Hillan,Robert L. Cohen,Audrey Goddard,David Botstein,Avi Ashkenazi +17 more
TL;DR: Certain tumours may escape FasL-dependent immune-cytotoxic attack by expressing a decoy receptor that blocks FasL, which was amplified in about half of 35 primary lung and colon tumours studied and DcR3 messenger RNA was expressed in malignant tissue.